www.InvestorStemCell.com Not an InvestorStemCell member? Sign Up!

Sign Up

Investor Stem Cell is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible advancements in the regenerative medicine sector.

bpv

Bulletproof! Stem Cells Exhibit Unusual Absorption

Bulletproof Nuclei? Stem Cells Exhibit Unusual Absorption Mon, 04/21/2014 – 12:39pm Stem cells– the body’s master cells– demonstrate a bizarre property never before seen...

HarvHeart1

Bioheart, Inc. to Present Clinical Trial Results

press release April 22, 2014, 8:03 a.m. EDT Bioheart, Inc. to Present Clinical Trial Results at the Age Management Medicine Group Conference SUNRISE, FL,...

ImmunoCellular Therapeutics Announces ICT-107 Phase II Data

22 April 2014

ImmunoCellular Therapeutics Announces ICT-107 Phase II Data Abstract Accepted for Oral Presentation at the 2014 ASCO Annual Meeting LOS ANGELES, April 21, 2014 /PRNewswire/ — ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that the abstract describing the Company’s phase II trial of dendritic cell-based cancer vaccine ICT-107 in newly diagnosed glioblastoma (GBM) has been accepted for an oral presentation at the 2014 American Society for Clinical Oncology (ASCO) annual meeting, to be held in Chicago May 30-June 3, 2014. The abstract accepted for oral presentation is titled, “A randomized, double–blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients.” The principal investigator on the study, Patrick Y. Wen, MD, Director, Center for Neuro-Oncology, Dana Farber Cancer Institute, and Professor Neurology, Harvard Medical School, will present during the session titled, Central Nervous System Tumors, on Sunday, June 1(st) at 8:00-11:00 am...

New Study to Target Cancer Stem Cell Drug Resistance Pathway

22 April 2014

Posted by: Maureen Newman April 21, 2014 Cancer stem cellsCancer stem cells and their acquired resistance to cancer drugs are the subject of investigation in a study co-authored by researchers at University of California San Diego...

International Stem Cell Corporation to Provide an Update on Its Parkinson’s Disease Program

22 April 2014

International Stem Cell Corporation to Provide an Update on Its Parkinson’s Disease Program at the 66th American Academy of Neurology Annual Meeting . International Stem Cell Corporation to Provide an Update on Its Parkinson’s Disease Program...

Welcome to Investor Stemcell! New to the site? Take a minute and Sign Up Today!